Sy-Shi Wang, Ph.D.

Janssen Pharmaceutical

Disclosure(s): Janssen Research & Development LLC: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-1104) Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT